Soleno Therapeutics’ (SLNO) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Soleno Therapeutics (NASDAQ:SLNO) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $19.00 price target on the stock.

Soleno Therapeutics Stock Up 1.8 %

Soleno Therapeutics stock opened at $4.98 on Thursday. The firm has a market cap of $49.76 million, a PE ratio of -1.64 and a beta of 0.11. Soleno Therapeutics has a 52-week low of $0.85 and a 52-week high of $6.20. The company’s 50 day moving average is $4.78 and its two-hundred day moving average is $3.97.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Tuesday, August 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.11). On average, equities research analysts anticipate that Soleno Therapeutics will post -2.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Soleno Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP acquired a new stake in shares of Soleno Therapeutics in the first quarter valued at about $64,000. Millennium Management LLC acquired a new position in Soleno Therapeutics during the fourth quarter worth about $91,000. Renaissance Technologies LLC raised its position in shares of Soleno Therapeutics by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 49,754 shares of the company’s stock valued at $99,000 after buying an additional 4,800 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Soleno Therapeutics by 67.9% in the second quarter. Geode Capital Management LLC now owns 54,648 shares of the company’s stock valued at $234,000 after buying an additional 22,092 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Soleno Therapeutics by 1,164,483.3% in the first quarter. JPMorgan Chase & Co. now owns 69,875 shares of the company’s stock valued at $150,000 after buying an additional 69,869 shares during the last quarter.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.